Skip to content
Accessibility help

Search NICE…

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE

Search results

Skip to results

Type

TypeGuidance (16)

Status

StatusPublished (14)Topic prioritisation (1)

Last updated

Last updatedLast 3 months (0)Last 6 months (0)Last year (3)Last 3 years (4)

Guidance programme

Guidance programmeClinical guidelines (3)NICE guidelines (3)Technology appraisal guidance (13)

Showing 16 to 16 of 16 results for guselkumab

Sort by

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA711)
This guidance has been updated and replaced by NICE technology appraisal guidance TA815.
Result type
Withdrawn guidance

Previous page
1
Current page 2
Page 2 of 2

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS) Clinical Knowledge Summaries
British National Formulary (BNF) British National Formulary
BNF for Children (BNFC) British National Formulary for Children
Life sciences
Library and knowledge services

What NICE does
Implementing NICE guidance
Get involved
About us
Careers
News, blogs and podcasts
Newsletters and alerts
Contact us
Leave feedback
Reusing our content
NICE UK Open Content Licence
Syndicate our content
Events

Facebook
X
YouTube
LinkedIn

Accessibility
Freedom of information
Glossary
Terms and conditions
Privacy notice
Cookies

© NICE 2026. All rights reserved. Subject to Notice of rights.